Bright Peak is a privately held biotechnology company based in San Diego, CA and Basel, Switzerland developing innovative cytokine therapeutics that are uniquely engineered to precisely tune and c .
- BPT567, a first-in-class PD1-IL18 immunocytokine, delivers coordinated PD-1 blockade and potent IL-18 signaling to PD-1+ T effector cells resulting in striking antitumor activity - - BPT331, a PD1-IL2
Bright Peak Therapeutics to Present Innovative Best-in-Class and Multifunctional Regulatory T Cell (Treg) Enhancers at the 10th International Conference on Autoimmunity: Mechanisms and Novel Treatments GlobeNewswire October 20, 2022 – First presentation of BPT264, the only Treg-targeting IL-2 for autoimmune disease that is both IL2Rα-enhanced and IL2Rβ-dead, displaying best-in-class preclinical properties .
- First presentation of BPT264, the only Treg-targeting IL-2 for autoimmune disease that is both IL2Ra-enhanced and IL2Rß-dead, displaying best-in-class preclinical properties - - Introduction
- Internationally renowned researchers Gordon Freeman, Ph.D., Thomas Gajewski, M.D., Ph.D., Jason Luke, M.D., Ignacio Melero, M.D., Ph.D., and Anthony.